Hospitalizations related to herpes zoster infection in the Canary Islands, Spain (2005-2014)

Amós García-Rojas¹, Ruth Gil-Prieto²*, Domingo Ángel Núñez-Gallo¹, Petra Matute-Cruz¹ and Angel Gil-de-Miguel²

Abstract

Background: Herpes zoster is an important problem of public health especially among the elderly in Spain.

Methods: A population-based retrospective epidemiological study to estimate the burden of herpes zoster requiring hospitalization in the Canary Islands, Spain was conducted by using data from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos. Records of all patients admitted to hospital with a diagnosis of herpes zoster in any position and cases of primary diagnosis (ICD-9-MC codes 053.0–053.9) during a 10-year period (2005–2014), were selected.

Results: A total of 1088 hospitalizations with a primary or secondary diagnosis of herpes zoster were identified during the study period. Annually there were 6.99 hospitalizations by herpes zoster per 100,000 population. It increases with age reaching a maximum in persons ≥85 years of age (43.98 admissions per 100,000). Average length of hospitalization was 16 days and 73 patients died, with a case-fatality rate of 4.03%. In 22% of the cases hospitalized, herpes zoster was the primary diagnosis.

Conclusion: The hospitalization burden of herpes zoster in adults in the Canary Islands was still important during the last decade and justify the implementation of preventive measures, like vaccination in the elderly or other high risk groups to reduce the most severe cases of the disease.

Keywords: Hospitalizations, Herpes zoster, Epidemiology

Background

It is estimated that the 15% of the global population will suffer from at least one episode of herpes zoster during their lifetime [1]. With an increase in age, loss of cell-mediated immunity and immunosenescence, complications of herpes zoster may occur [2, 3], being post-herpetic neuralgia the most frequent and limiting [4, 5], causing important pain to 15–40% of the patients majorly impacting quality of life [3, 6].

Currently in Spain, there are two licensed varicella vaccines indicated for active immunization for the prevention of varicella in susceptible individuals 12 months of age or older. In addition, one licensed herpes zoster vaccine indicated for prevention of herpes zoster in healthy immunocompetent individuals 60 years of age and older susceptible of having herpes zoster and post-herpetic neuralgia caused by varicella zoster virus (VZV) [7]. Herpes zoster vaccine is not funded as part of a government immunisation program. Starting in 2016 varicella vaccines were included as part of the government funded immunisation program at 15 months and 3 years of age in the Canary Islands. It is essential to study the burden of herpes zoster and its epidemiology in order to correctly evaluate the efficacy, effectiveness and impact of different preventive strategies, like the use of varicella vaccine in routine vaccination schedules in children, susceptible adolescents or herpes zoster vaccine in the elderly or adults in high risk groups. The use of hospitalization data bases for studying the epidemiology of different infectious diseases is widespread as they are

* Correspondence: ruth.gil@urjc.es
² Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Avda. Atenas s/n, 28922 Madrid, Spain
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
not subject to mayor under-diagnosis and give a good spectrum of the most severe cases of the disease. [8].

The objective of this study was to report the hospitalization burden related to herpes zoster infection in the Canary Islands from 2005 to 2014.

**Methods**

A retrospective epidemiological study was performed by using hospitalization discharge registers from the national information system for hospital data (CMBD, Conjunto Mínimo Básico de Datos), from the Spanish Ministry of Health. All the registers for the Canary Islands, with an average population of 2,033,201, reported from January 1st, 2005 through December 31st, 2014 were selected. The national information system for hospital data (Conjunto Mínimo Básico de Datos; CMBD) includes an estimated 98% of discharges in public hospitals, covering 99.5% of the Spanish population. [9–11].

The 9th International Classification of Diseases ICD-9-CM (CIE-9-MC) [12] codes for herpes zoster (053.0, 053.1, 053.2, 053.3, 053.4, 053.5, 053.6, 053.7, 053.8, 053.9) were selected. All herpes zoster related hospitalizations in a) any diagnostic position and b) first diagnostic position were analyzed.

This data base has been extensively used in epidemiological studies evaluating the burden of disease and changes in epidemiology of different diseases like varicella, respiratory syncytial virus or anaphylaxis, among others [13–15].

For each case, information on age, sex, outcome (recovery, death…) and length of stay was obtained.

**Statistics**

The unit of analyses was the hospital discharge. The annual hospitalization rate (annual number of hospital admissions per 100,000 population), average length of hospital stay (ALOS), mortality rate (annual number of deaths at hospital per 100,000 population) and case-fatality rate (annual number of deaths at hospital/annual number of hospital admissions; %) were calculated. Data from the age-specific annual municipal population registries (corrected by the CMBD coverage) were used as the denominator. It was assumed that the distribution by age of the population covered by this data base was equal to the distribution of the general population of the Canary Islands.

All analyses were stratified by age group: < 50 years, 50–54 years, 55–59 years, 60–64 years, 65–69 years, 70–74 years, 75–79 years, 80–84 years and ≥85 years. We also reported the crude and age-standardized (EU27 + EFTA 2013 standard population) total hospitalization, total mortality, and total case fatality rates. ANOVA or Kruskal Wallis tests were used to evaluate differences in means and distributions. Poisson regression was used to assess differences in the hospitalization rate over the study period.

In all tests the significance level used was \( p < 0.05 \). Statistical analyses were performed using the IBM Statistical Package for Social Sciences (IBM SPSS/PASW for windows, version 21.0, Chicago, IL, USA).

The patient information was anonymized and de-identified prior to the analysis. Local ethics committee (Comité de Ética de la Investigación de la Universidad Rey Juan Carlos) ruled that no formal ethics approval was required in this particular case.

**Results**

A total of 1088 hospital discharges related to herpes zoster infection were reported during the 10-year study period in the Canary Islands, with an annual crude hospitalization rate of 5.35 (95%-CI 5.03–5.67) cases per 100,000 inhabitants (age standardized hospitalization rate = 6.99, 95%-CI = 6.57–7.43). The average length of stay was 15.82 (SD 18.84) days and their mean age was 63.69 (SD 19.89) years old. Sixty-eight percent of the hospitalizations occurred in patients 60 years of age or older and 35% in patients aged more than 75. There were a total of 73 deaths among the patients hospitalized with herpes zoster during the study period. The mortality rate was 0.36 (95%-CI = 0.28–0.44) deaths per 100,000 inhabitants (age standardized: 0.51, 95%-CI = 0.40–0.65) and the case fatality rate was 6.71% (95%-CI = 5.22–8.20, age standardized 4.03%, 95%-CI = 2.78–5.86).

Analysis restricting to 263 herpes zoster cases registered in the first diagnostic position only were reported in Additional file 1: Table S1 yielding a total hospitalization rate of 1.29 (95%-CI = 1.14–1.45) hospitalizations in the first diagnostic position per 100,000 inhabitants of the Canary Islands (1.54, 95%-CI = 1.35–1.74 per 100,000 inhabitants after age standardization). Of these hospitalizations, 47 (18%) were related to herpes zoster with meningitis (053.0), 56 (21%) to herpes zoster with other nervous system complications (053.1), 39 (15%) to herpes zoster with opthalmic complications (053.2), 36 (14%) to herpes zoster with other specified complications (053.7), 1 (0%) to herpes zoster with unspecified complications (053.8), and 84 (32%) to herpes zoster without complications (053.9).

When analyzing rates per group of age, both hospitalization and mortality rates increased in a statistically significant way with age, reaching the maximum values in the elderly (>84 years old) with 43.98 cases per 100,000 inhabitants (95%-CI = 36.08–51.88) and 5.17 deaths per 100,000 inhabitants (95%-CI: 2.46–7.89), respectively (Table 1). Case-fatality rates also increased with age, but statistical significance was not reached. (Table 1). The highest case-fatality rate was found in the 75–79 group of age with 12.21% (CI 95% 6.61–17.82).
The hospitalization rates did not suffer important variations during the study period, except for the oldest group of age, 85+ where there was a significant increase in the hospitalization rates ($p < 0.05$; Table 2).

### Discussion

This is the first study to assess the hospital burden of herpes zoster in the Canary Islands and its trend in the last decade. Obtained crude hospitalization rates during the period of 5.35 (6.99 when age-standardized) cases per 100,000 inhabitants are in line with the regional results (6.1 cases per 100,000 in the Canary Islands) published in a national study with data from 1998 to 2004 for adults older than 30 years old [15]. In that study it was seen that the Canary Islands had the lowest hospitalization rate and the longest average length of stay at hospital of all the regions of Spain, suggesting that only very severe cases were being admitted. In the current study, a slightly shorter length of hospitalization of 16 days (vs. 20 days in 1998–2004) was found.

When comparing hospitalization rates in the Canary Islands with Spanish national figures from 2005 to 2010, our results are significantly lower than the reported national rate of 10.33 hospitalizations per 100,000 inhabitants [16]. Regional differences of the epidemiology of herpes zoster regarding Spanish national data may be explained by the special characteristics of age distribution of the population of the Canary Islands, with an important number of young immigrants from African countries and of old immigrants from Northern European countries. Another contributing factor may the special geographic characteristics of the Canary Islands located in a tropical area where the seroprevalence of varicella may be lower.

The dramatic increase of hospitalization rates with age, especially from 60 to 70 years of age, follows the pattern observed in other occidental countries, such as the United Kindom [17, 18].

The main result of this study is to show the important hospital burden of herpes zoster, especially in the elderly. The increase of the hospitalization rate in the oldest group of age is very interesting. But this increase has been previously explained as a result of the increase in mean age of the group of 85+ years old due to population ageing and the increasing life expectancy and was

### Table 1: Hospitalization rate, mortality rate and case-fatality rate related to herpes zoster infection by group of age in the Canary Islands, Spain (2005–2014)

| Group of age (years) | N   | Cases | Hospitalization rate (cases per 100,000 /CI95%) | Mortality rate (deaths per 100,000 /CI95%) | Case-fatality rate (% /CI95%) | Average length of hospital stay (days/SD) |
|---------------------|-----|-------|-----------------------------------------------|-------------------------------------------|-------------------------------|----------------------------------------|
| <50                 | 1,420,480 | 241 | 1.70 (1.48–1.91) | 0.04 (0.004–0.07) | 2.08 (0.28–3.87) | 12.73 (6.12–17.31) |
| 50–54               | 132,854 | 49  | 3.69 (2.66–4.72) | 0.23 (0.00–0.48) | 0.12 (0.10–0.14) | 13.69 (6.12–17.31) |
| 55–59               | 112,155 | 61  | 5.44 (4.07–6.80) | 0.27 (0.00–0.48) | 0.10 (0.08–0.12) | 11.86 (6.12–17.31) |
| 60–64               | 97,906  | 109 | 11.13 (9.04–13.22) | 0.82 (0.25–1.38) | 0.73 (0.25–1.38) | 21.69 (18.01–25.38) |
| 64–69               | 82,777  | 123 | 14.86 (12.23–17.49) | 1.09 (0.37–1.80) | 0.72 (0.25–1.38) | 20.95 (18.01–25.38) |
| 70–74               | 70,038  | 128 | 18.28 (15.11–21.44) | 0.71 (0.00–0.48) | 3.91 (0.12–10.35) | 15.36 (12.01–18.66) |
| 75–79               | 55,721  | 131 | 23.51 (19.49–27.54) | 2.87 (1.46–4.28) | 6.61 (1.12–10.35) | 17.04 (14.70–19.38) |
| 80–84               | 35,214  | 127 | 36.07 (29.79–42.34) | 2.84 (1.08–4.60) | 7.87 (1.39–12.57) | 14.94 (12.01–17.84) |
| >84                 | 26,056  | 119 | 43.98 (36.08–51.88) | 5.17 (2.46–7.89) | 5.89 (1.29–10.35) | 14.70 (12.01–17.84) |
| Total               | 1,088   | 535 | 5.35 (5.03–5.67) | 0.36 (0.28–0.44) | 0.36 (0.28–0.44) | 15.82 (13.50–18.14) |

Total (age-standardized)$^a$:
- Hospitalization rate (6.99 (5.03–6.67) cases per 100,000 /CI95%)
- Mortality rate (4.03 (2.78–5.86) deaths per 100,000 /CI95%)
- Case-fatality rate (5.22 (3.19–12.56) % /CI95%)
- Average length of hospital stay (18.84 (15.82–21.86) days/SD)

$^a$standardized to the EU-27 + EFTA standard population from http://ec.europa.eu/eurostat/en/web/products-manuals-and-guidelines/-/KS-RA-13-028
| Group of age (years) | N | Rate (per 100,000/CI95%) | N | Rate | N | Rate | N | Rate | N | Rate | N | Rate | N | Rate |
|---------------------|---|-------------------------|---|-------|---|-------|---|-------|---|-------|---|-------|---|-------|
| <50                 | 27 | 1.93                    | 21 | 1.49  | 18 | 1.27  | 16 | 1.11  | 11 | 0.98  | 10 | 0.84  | 10 | 0.84  |
| 50–54               | 8  | 7.18                    | 2  | 1.73  | 5  | 4.16  | 5  | 3.98  | 5  | 4.59  | 5  | 3.70  | 4  | 3.46  |
| 54–59               | 8  | 5.10                    | 7  | 6.99  | 5  | 4.83  | 2  | 1.86  | 8  | 7.19  | 10 | 8.73  | 21 | 10.00 |
| 60–64               | 7  | 8.19                    | 7  | 7.87  | 13 | 13.98 | 9  | 9.39  | 11 | 11.14 | 12 | 11.92 | 16 | 15.69 |
| 64–69               | 5  | 7.05                    | 13 | 17.80 | 10 | 13.79 | 10 | 13.05 | 14 | 17.28 | 12 | 13.80 | 19 | 21.29 |
| 70–74               | 11 | 16.48                   | 10 | 14.47 | 15 | 14.52 | 12 | 14.95 | 16 | 22.64 | 15 | 21.85 | 12 | 17.20 |
| 75–79               | 5  | 11.18                   | 4  | 8.48  | 19 | 38.32 | 12 | 22.50 | 15 | 26.61 | 16 | 26.93 | 13 | 21.10 |
| 80–84               | 11 | 20.23                   | 4  | 13.72 | 8  | 24.62 | 10 | 31.44 | 11 | 32.72 | 22 | 61.80 | 11 | 29.13 |
| >84                 | 5  | 22.08                   | 7  | 29.94 | 7  | 30.17 | 12 | 40.04 | 9  | 34.89 | 19 | 68.57 | 13 | 44.55 |
| Total               | 84 | 4.36                    | 75 | 3.84  | 96 | 4.84  | 90 | 4.42  | 116| 5.63  | 131| 6.31  | 121| 6.12  |
| Total (age-standardized)* | 84 | 4.36 | 75 | 3.84 | 96 | 4.84 | 90 | 4.42 | 116| 5.63 | 131| 6.31 | 121| 6.12 |

*standardized to the EU-27 + EFTA standard population from http://ec.europa.eu/eurostat/en/web/products-manuals-and-guidelines/-/KS-RA-13-028
shown not to be related with the more or less extensive use of the varicella vaccine in young children [16]. Supporting this theory is the 3.2% annual increase of hospitalization rate due to any cause that was reported in Spain over the study period.

Although the use of population data bases to study infectious diseases epidemiology has been extensively proven worldwide, it has some limitations that should be considered. First, considering herpes zoster diagnosis code in any diagnosis position could overestimate the real hospital burden related to herpes zoster infection, as patients could be admitted due to other causes. For the purpose of the present project, we considered primarily the presence of herpes zoster in any diagnostic position because having herpes zoster infection could worsen or lengthen the hospitalization by any other cause thus contributing to the burden of herpes zoster. For completeness and to get a better perspective on the incidence of herpes zoster hospitalizations and its complications, we reported results when using only the first diagnostic position in the text and the appendix. It should be mentioned that only hospitalized cases are included in this study and hence only the most severe spectrum of the disease. Our results should therefore not be interpreted as disease incidence as the outpatient setting is not included. Although CMBD does not necessarily include microbiological diagnosis, the clinical diagnosis of herpes zoster and post herpetic neuralgia is very specific and some studies including chart reviews have shown a positive predictive value between 89–96% [19].

Conclusion
The hospitalization burden of herpes zoster in adults in the Canary Islands was still important during the last decade and justify the implementation of preventive measures, like vaccination in the elderly or high risk groups, to at least reduce the most severe cases of the disease.

Additional file

Additional file 1: Table S1 Hospitalization rate, mortality rate and case-fatality rate related to herpes zoster infection by group of age in the Canary Islands; Spain (2005–2014) – Principal Diagnosis only. (DOCX 13 kb)

Abbreviations
ALOS: Average length of hospital stay; CI: Confidence interval; CMBD: Conjunto Mínimo Básico de Datos; ICD: International Classification of Diseases; VZV: Varicella zoster virus

Acknowledgements
Thanks to the Subdirección General del Instituto de Información Sanitaria for providing the information upon which this study is based.

Funding
This study did not receive funding.

Availability of data and materials
Data belong to the Spanish Ministry of Health and can be found in https://www.msssi.gob.es/estadEstudios/estadisticas/cmbd.htm.

Authors’ contributions
AGR and AGM participated in the study design, RGP, DANG, PMC performed the statistical analysis. All the authors interpreted the analysis and drafted the manuscript. All the authors read and approved the final manuscript.

Ethics approval and consent to participate
The patient information was anonymized and de-identified prior to the analysis. Local ethics committee (Comité de Ética de la Investigación de la Universidad Rey Juan Carlos) ruled that no formal ethics approval was required in this particular case.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Epidemiology and Prevention Service, Public Health General Direction, Las Palmas de Gran Canaria, Spain. 2Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Avda. Atenas s/n, 28922 Madrid, Spain.

Received: 8 November 2016 Accepted: 16 August 2017

References
1. Vázquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med. 2005;352(5):439–40.
2. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med. 1997;157(11):1209–13.
3. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975; 25(157):571–5.
4. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.
5. Helgason S, Petunsson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321(7264):794–6.
6. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Derm. 1957;75(2):193–8.
7. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Shingles Prevention Study Group, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352(22):2271–84.
8. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalisations: the pre-vaccination era. J Infect Dis. 2000;181:987–905.
9. Subdirección General de Información Sanitaria e Innovación. Sistema de Información Sanitaria del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2014. https://www.msssi.gob.es/estadEstudios/estadisticas/sistinSanSNS/pdf/SIN.pdf. Accessed 22 Aug 2017.
10. Rivero Cuadrado A. Análisis y desarrollo de los GDR en el Sistema Nacional de Salud. Available: http://www.msssi.gob.es/estadEstudios/estadisticas/docs/analisys.pdf. Accessed 22 Aug 2017.
11. Sevilla F. La universalización de la atención sanitaria. Sistema Nacional de Salud y Seguridad Social. Fundación Alternativas. Documento de trabajo 86/2006. http://www.egc-sociales.prd00/groups/public/documents/binario/ 51587.pdf. Accessed 22 Aug 2017.
12. Ministerio de Sanidad y Consumo. Clasificación Internacional de Enfermedades 9ª revisión, modificación clínica. (http://www.msc.es/estadEstudios/estadisticas/normalizacion/clasificacion/home.htm) (Accessed September 2016).
13. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory Syncytial virus Bronchiolitis in children up to 5 years
of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore). 2015;94:e831.

14. Tejedor-Alonso MA, Moro-Moro M, Mosquera González M, Rodriguez-Alvarez M, Pérez Fernández E, Latasa Zamalloa P, et al. Increased incidence of admissions for anaphylaxis in Spain 1998–2011. Allergy. 2015;70:880–3.

15. Gil A, Gil R, Alvaro A, San Martin M, González A. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998–2004). BMC Infect Dis. 2009;9:55.

16. Gil-Prieto R, Walter S, González-Escalada A, García-Garcia L, Martín-García P, Gil-de-Miguel A. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine. 2014;32(2):277–83. doi:https://doi.org/10.1016/j.vaccine.2013.11.008. Epub 2013 Nov 22.

17. Brisson M, Edmunds WJ. Epidemiology of Varicella-zoster virus in England and Wales. J Med Virol. 2003;70(Suppl 1):S9–14.

18. Bramley JC, Jones IG. Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health. 2000;3(4):282–7.

19. Miller E, Marshall R, Verdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol. 1993;4:222–30.